Sanofi SNY, -0.18% on Friday released positive trial results for its investigational eczema treatment, notching a win that stemmed from the company’s recent dealmaking to bolster its immunology pipeline.
The eczema treatment was a key asset Sanofi added to its pipeline in 2021 with its $1.1 billion acquisition of the clinical-stage biopharma company Kymab. Amlitelimab faces competition including Sanofi and Regeneron Pharmaceuticals Inc.’s REGN, +1.42% own blockbuster Dupixent and rocatinlimab, which Amgen Inc. AMGN, -0.79% is jointly developing with Kyowa Kirin KYKOY, +4.91%.
Amlitelimab also works differently from Dupixent, targeting the OX40-Ligand, a key immune regulator and aiming to restore balance between pro-inflammatory and regulatory T cells.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: nbcchicago - 🏆 545. / 51 Read more »
Source: NBCNewYork - 🏆 270. / 63 Read more »